Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cladribine + leucovorin + cytarabine + mitoxantrone + peripheral blood stem cells
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
CLAM + PBSC is a salvage chemotherapy regimen followed by peripheral blood stem cell (PBSC) transplantation, primarily utilized in the treatment of relapsed or refractory acute myeloid leukemia (AML). The chemotherapy component, CLAM, consists of cladribine, leucovorin, cytarabine (Ara-C), and mitoxantrone. Cladribine, a purine nucleoside analog, acts as a biochemical modulator that enhances the intracellular accumulation of cytarabine triphosphate (Ara-CTP), the active metabolite of cytarabine, thereby increasing its cytotoxic efficacy. Mitoxantrone, a type II topoisomerase inhibitor and DNA intercalator, provides additional antineoplastic activity. Leucovorin is included to modulate nucleoside metabolism and potentially enhance the effects of the pyrimidine analogs. Following the intensive chemotherapy, peripheral blood stem cells are infused to restore hematopoietic function and facilitate bone marrow recovery.
- Other names
- CLAM regimenCLAM-PBSCCLAM chemotherapyCLAM protocol
02
Targets
TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cladribine + leucovorin + cytarabine + mitoxantrone + peripheral blood stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cladribine + leucovorin + cytarabine + mitoxantrone + peripheral blood stem cells.